Vanda Pharmaceuticals News

Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US

Vanda Pharmaceuticals (VNDA) said late Thursday it is now allowed to commercialize Ponvory, or ponesimod, in the US. The company said the move follows the transfer of ownership of the US new drug appl

MT Newswires17:12

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New

PR Newswire05:20

Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S.

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY (ponesimod) has been transferred

Benzinga05:07

Express News | Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for Ponvory®

Breakings04:48

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024. The

PR NewswireMay 30 02:17

Vanda Pharma Rejects Future Pak's Sweetened Takeover Bid

By Dean Seal The board of Vanda Pharmaceuticals has rejected Future Pak's sweetened proposal for a takeover at $7.25 to $7.75 a share, saying the offer is still too low. The biopharmaceutical compan

WSJMay 25 05:17

Vanda Pharmaceuticals: Future Pak's Offer to Buy Company for $7.25 to $7.75 a Share Plus Certain Contingent Value Rights Substantially Undervalues Company

Vanda Pharmaceuticals: Future Pak's Offer to Buy Company for $7.25 to $7.75 a Share Plus Certain Contingent Value Rights Substantially Undervalues Company

Dow JonesMay 25 04:48

Express News | Vanda Pharmaceuticals Inc - Board Has Rejected Proposal

BreakingsMay 25 04:46

Express News | Vanda Pharmaceuticals Board of Directors Determines That Revised Unsolicited Takeover Proposal Is Not in the Best Interests of the Company and Its Shareholders

BreakingsMay 25 04:46

Vanda Pharmaceuticals Announces Positive Results From Second Phase III Study Of Tradipitant, Confirming Efficacy In Preventing Motion Sickness-Related Vomiting

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two effica

BenzingaMay 15 20:46

Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates

Yahoo FinanceMay 11 03:24

Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference

The following is a summary of the Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript:Financial Performance:Vanda Pharmaceuticals posted total revenues of $47.5 million for Q1 2024, re

Futu NewsMay 9 22:08 · Conference Call

Vanda Pharmaceuticals | 10-Q: Quarterly report

SEC announcementMay 9 19:12 · Announcements

Q1 2024 Vanda Pharmaceuticals Inc Earnings Call

Yahoo FinanceMay 9 18:43

Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft

BenzingaMay 9 17:49

Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript

Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 9 09:48

Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate

Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. The company reported quarterly sales of $47.462 million

BenzingaMay 9 04:27

Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M

04:01 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M

MT NewswiresMay 9 04:01

Vanda Pharmaceuticals 1Q Loss $4.15M >VNDA

Vanda Pharmaceuticals 1Q Loss $4.15M >VNDA

Dow JonesMay 9 04:01

Vanda Pharmaceuticals 1Q Rev $47.5M >VNDA

Vanda Pharmaceuticals 1Q Rev $47.5M >VNDA

Dow JonesMay 9 04:01